Literature DB >> 356957

Immunologic aspects and pathology of the malignant lymphomas.

C W Berard, E S Jaffe, R C Braylan, R B Mann, K Nanba.   

Abstract

Malignant lymphomas have traditionally been classified on solely morphologic grounds. With new immunologic and cytochemical techniques, it has been possible to characterize normal cells of the T-lymphocytic, B-lymphocytic, and monocyte-macrophage systems. Application of these methodologies to malignant lymphomas has established their nature as neoplasmas of the immune system. Within the B-lymphocytic system it is possible to identify subpopulations responsible for Burkitt's tumor, follicular (nodular) lymphomas, lymphocytic lymphomas of intermediate differentiation and well differentiated lymphocytic lymphomas. The T-lymphocytic system includes lymphoblastic lymphomas, mycosis fungoides, and Sezary's syndrome. Large cell lymphomas are diverse but the majority are tumors of transformed lymphocytes, usually of the B-lymphocytic system. The precise nature of the neoplastic cells of Hodgkin's disease, i.e., Reed-Sternberg cells and their mononuclear counterparts, has not yet been established. Despite previous suggestions of a B-lymphocytic or T-lymphocytic origin, recent studies utilizing in vivo cultivation have strongly suggested derivation from the monocyte-macrophage system.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 356957     DOI: 10.1002/1097-0142(197808)42:2+<911::aid-cncr2820420713>3.0.co;2-g

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

Review 1.  Malignant lymphomas--a conceptual understanding of morphologic diversity. A review.

Authors:  R B Mann; E S Jaffe; C W Berard
Journal:  Am J Pathol       Date:  1979-01       Impact factor: 4.307

2.  Principles and present status of a prospective multicenter study on the clinical relevance of the Kiel classification.

Authors:  G Brittinger; U Schmalhorst; H Bartels; H H Fülle; H Gerhartz; G Gremmel; T Grisar; H J Grupp; U Gunzer; D Huhn; K M Koeppen; B Kubanek; H Leopold; H Löffler; G W Löhr; L Nowicki; U Rühl; M Schmidt; A Stacher; H Theml; K Lennert
Journal:  Blut       Date:  1981-09

3.  Acid alpha-naphthyl acetate esterase activity in human neoplastic lymphoid cells. Usefulness as a T-cell marker.

Authors:  D M Knowles; J P Halper; G A Machin; W Sherman
Journal:  Am J Pathol       Date:  1979-07       Impact factor: 4.307

4.  Childhood lymphoma in Yorkshire.

Authors:  A M Davison; P A McKinney; C C Bailey; I Lewis; R A Cartwright; C O'Brien
Journal:  J Clin Pathol       Date:  1992-02       Impact factor: 3.411

5.  Null cell adenoma of the human pituitary.

Authors:  K Kovacs; E Horvath; N Ryan; C Ezrin
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1980

6.  S-100+ lymph node neoplasm. Report of a case with histological AL and immunological features intermediate between T cell lymphoma and malignant histiocytosis.

Authors:  L P Ruco; A Stoppacciaro; P Barsotti; D Vitolo; M Mirolo; A M Cassano; C Guglielmi; F Mandelli; S Uccini; C D Baroni
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984

7.  The immunologic characterization of 95 nodal and extranodal diffuse large cell lymphomas in 89 patients.

Authors:  R S Doggett; G S Wood; S Horning; R Levy; R F Dorfman; J Bindl; R A Warnke
Journal:  Am J Pathol       Date:  1984-05       Impact factor: 4.307

8.  Malignant lymphomas: cell surface markers and advances in classification.

Authors:  J A Strauchen
Journal:  West J Med       Date:  1981-10

9.  Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse.

Authors:  S H Swerdlow; J A Habeshaw; L J Murray; H S Dhaliwal; T A Lister; A G Stansfeld
Journal:  Am J Pathol       Date:  1983-11       Impact factor: 4.307

10.  Immunophenotypic analysis of childhood Burkitt's lymphoma in the West Midlands 1957-1986.

Authors:  T J Jones; N A Coad; K R Muir; S E Parkes; C D Evans; J R Mann
Journal:  J Clin Pathol       Date:  1995-01       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.